3. HLH and Macrophage Activation Syndrome (Combined)

Quick Recap

Autoimmune & Rheumatology System, Protocol 3/5. Combines HLH and Macrophage Activation Syndrome (MAS) into a single protocol since MAS IS hemophagocytic lymphohistiocytosis occurring specifically in the context of rheumatologic disease — the same underlying hyperinflammatory syndrome with a rheumatology-specific name and typical trigger context.

1. Definition and Terminology

Hemophagocytic lymphohistiocytosis (HLH) = a life-threatening hyperinflammatory syndrome caused by uncontrolled activation of macrophages/histiocytes and cytotoxic T-cells, driving a cytokine storm that causes multiorgan dysfunction.

Macrophage activation syndrome (MAS) = the term used when HLH occurs in the setting of an underlying RHEUMATOLOGIC disorder (most classically systemic juvenile idiopathic arthritis/Still disease, but also SLE and other connective tissue diseases) — MAS and HLH are the SAME pathophysiologic process, and management principles substantially overlap, though MAS-specific trigger recognition (disease flare vs superimposed infection) carries its own nuance (Section 6).

Primary (genetic) HLH: typically presents in childhood, caused by inherited defects in cytotoxic T-cell/NK-cell granule-mediated killing pathways.

Secondary (acquired) HLH: triggered by infection (especially EBV and other viral infections), malignancy (particularly lymphoma), autoimmune disease (= MAS), or immunotherapy (CAR-T-associated HLH-like syndrome) — the dominant presentation encountered in adult ICU practice.

2. When to Suspect

Marked cytopenia of TWO OR THREE cell lineages, ESPECIALLY IF ASSOCIATED WITH FEVER — this is the core trigger pattern, particularly in a patient with known or suspected autoimmune disease (raising MAS specifically) or an unexplained hyperinflammatory/sepsis-like picture not responding to standard antimicrobial therapy.

In SLE patients specifically: any patient with marked bi- or tri-lineage cytopenia and fever should have MAS actively considered as part of the thrombocytopenia/cytopenia differential, alongside ITP, TTP, aHUS, and antiphospholipid syndrome — suspicion and EARLY diagnosis are key to a better outcome, mirroring the treat-early-on-suspicion philosophy running throughout this Autoimmune & Rheumatology system.

3. Diagnostic Criteria

Laboratory pattern: elevated ferritin (often markedly, sometimes >10,000 ng/mL — though even lower elevations in the right context are significant), elevated triglycerides, elevated liver function tests, elevated LDH, LOW haptoglobin, LOW fibrinogen. Elevated soluble CD25 (soluble IL-2 receptor) and hemophagocytosis on bone marrow biopsy are classically seen, though bone marrow hemophagocytosis is neither perfectly sensitive nor specific — its absence does not exclude HLH/MAS, and its presence alone does not confirm it (hemophagocytosis can be seen incidentally in other severe illness states).

HLH-2004 diagnostic criteria (reference framework, 5 of 8 required): fever; splenomegaly; cytopenias affecting >=2 of 3 lineages; hypertriglyceridemia and/or hypofibrinogenemia; hemophagocytosis in bone marrow/spleen/lymph node/liver; low or absent NK-cell activity; ferritin >500 ng/mL (though clinically significant HLH often presents with MUCH higher levels); elevated soluble CD25.

HScore: an alternative, validated probability-based scoring tool incorporating similar variables (fever, organomegaly, cytopenia count, ferritin, triglycerides, fibrinogen, AST, and known immunosuppression/underlying disease) that generates a percentage probability of HLH rather than a binary threshold — useful when the HLH-2004 criteria are borderline or incompletely met.

Neither criteria set is perfectly validated for ADULT secondary HLH/MAS specifically (both were derived substantially from pediatric primary HLH populations) — apply clinical judgment and do not withhold treatment purely because a threshold score is not definitively met in a compelling clinical picture.

4. Immediate Stabilization (ABCDE)

General principle: suspicion and early diagnosis are key to a better outcome — this is a genuine treat-on-suspicion emergency, analogous to the empiric-treatment philosophy established for Pulmonary-Renal Syndrome and CAPS elsewhere in this system.

Circulation/Multi-organ support: standard ICU supportive care for the resulting multi-organ dysfunction (which can include hepatic failure, coagulopathy/DIC-like picture from hypofibrinogenemia, AKI, and CNS involvement in severe cases) — apply the relevant dedicated protocols (DIC, Acute Liver Failure, AKI) for organ-specific support while HLH-directed therapy is initiated.

Bleeding risk: hypofibrinogenemia can drive a genuine coagulopathy/bleeding risk — apply bleeding-driven (not prophylactic) blood product correction per the general DIC/Coagulopathy protocol principles (Hematology System), with cryoprecipitate specifically useful for the fibrinogen deficit.

Checklist:

5. Treatment — Etoposide/Dexamethasone-Based (HLH-94-Derived) and MAS-Specific Alternatives

Classic HLH-94-protocol-derived regimen (primarily for severe secondary HLH, especially with a strong inflammatory/cytotoxic-driven component): high-dose dexamethasone (typically 10 mg/m2/day, tapered over weeks) plus etoposide — etoposide directly targets and depletes the activated, dysregulated immune cells driving the cytokine storm, though its myelosuppressive/infection risk requires careful patient selection, particularly if an active infectious trigger is present.

MAS-specific approach (rheumatologic-disease-triggered): high-dose corticosteroids (often pulse-dose methylprednisolone) are typically FIRST-LINE, given MAS's context within an underlying autoimmune flare where steroids serve dual purposes (treating both the MAS hyperinflammation and the underlying rheumatologic disease activity). Anakinra (IL-1 receptor antagonist) has an increasingly established role, particularly in MAS and in cases where etoposide's myelosuppression/infection risk is a specific concern — targets the IL-1-driven inflammatory cascade with a more favorable safety profile for infection-associated or infection-uncertain presentations.

Treat the underlying trigger in parallel: infection-triggered HLH requires concurrent, aggressive treatment of the causative infection (particularly EBV-directed therapy where applicable, or standard antimicrobial therapy for other infectious triggers); malignancy-associated HLH requires oncologic evaluation and disease-directed therapy; MAS requires treatment of the underlying rheumatologic disease flare.

IVIG has also been used as an adjunct, particularly in infection-associated or milder presentations.

Refractory cases: additional cytokine-targeted therapies (e.g., tocilizumab for IL-6-driven components, ruxolitinib/JAK inhibition) and hematology/oncology-guided escalation per current, evolving evidence.

6. Distinguishing MAS Flare from Superimposed Infection — A Genuine Clinical Dilemma

In a rheumatologic disease patient with fever and worsening cytopenias, distinguishing a genuine MAS flare (requiring MORE immunosuppression) from a superimposed infection (requiring immunosuppression REDUCTION and antimicrobial therapy) is one of the most difficult and consequential judgment calls in this protocol — the two scenarios call for nearly opposite management approaches, yet can present almost identically. A thorough, aggressive infectious workup should ALWAYS be pursued in parallel with MAS-directed treatment consideration, and empiric antimicrobial coverage is often reasonable while the diagnostic picture clarifies, given the high stakes of missing either diagnosis. Very high ferritin elevations (particularly a RAPIDLY RISING trend) and a compatible disease-flare context favor MAS, while a clear infectious source/positive cultures favor infection — though genuine overlap and co-occurrence (infection PRECIPITATING a MAS flare) is common and should be actively considered rather than treated as mutually exclusive.

7. Investigations

Ferritin (trended, not just a single value), triglycerides, fibrinogen, LFTs, LDH, haptoglobin, CBC with differential (cytopenia trend), soluble CD25 (sIL-2 receptor) if available, bone marrow biopsy (hemophagocytosis assessment, also evaluates for underlying malignancy), NK-cell function testing if available (more relevant to primary HLH evaluation), EBV PCR/viral serologies and broader infectious workup, autoimmune disease activity markers if MAS is being considered in a known rheumatologic disease patient, coagulation panel (DIC-like picture from hypofibrinogenemia).

8. Organ Support

HLH/MAS-directed therapy (dexamethasone +/- etoposide, or pulse steroids +/- anakinra for MAS specifically) per Section 5; blood product support for coagulopathy/hypofibrinogenemia per bleeding-driven indications; standard organ-specific ICU supportive care for hepatic, renal, and hematologic dysfunction; concurrent aggressive treatment of the identified trigger.

9. Consultation Matrix

10. Monitoring Framework

Serial ferritin trend (a key treatment-response marker, alongside the other diagnostic labs), CBC/cytopenia trend, coagulation panel/fibrinogen, LFTs, renal function, temperature curve, ongoing infectious workup surveillance.

11. Complications

Multiorgan failure (hepatic, renal, hematologic), DIC-like coagulopathy/hemorrhage from hypofibrinogenemia, CNS involvement in severe cases, treatment-related infection risk (especially with etoposide-based cytotoxic therapy), death if diagnosis/treatment is delayed. Prevention: early suspicion and treatment initiation without excessive diagnostic delay, careful flare-vs-infection distinction with parallel empiric antimicrobial coverage where appropriate, bleeding-driven (not prophylactic) blood product correction. Rescue: escalation to tocilizumab/JAK inhibition for refractory cases, standard organ-specific rescue therapies (RRT, blood product support, hepatic support).

12. Escalation & De-escalation

Escalate: worsening cytopenias/ferritin trend despite first-line therapy -> escalate per the refractory-case options (tocilizumab, ruxolitinib, hematology-guided regimen intensification).

De-escalate: ferritin trending down, cytopenias improving, underlying trigger controlled -> taper immunosuppressive therapy per hematology/rheumatology guidance, continue trigger-directed treatment (infection course completion, oncologic therapy, or rheumatologic disease management).

13. ICU Discharge Criteria

Ferritin and cytopenia trend improving, underlying trigger identified and being treated/controlled, coagulopathy corrected, organ function stable or improving, hematology/rheumatology follow-up arranged for ongoing management and relapse surveillance.

14. Documentation & Medicolegal Checklist

15. Key Guidelines

Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.

16. Controversies

Neither the HLH-2004 criteria nor the HScore is well-validated specifically for ADULT secondary HLH/MAS, both having been derived substantially from different (largely pediatric primary HLH) populations — this is an acknowledged limitation affecting diagnostic confidence in the population most commonly encountered in adult ICU practice. The choice between etoposide-based and anakinra-based first-line therapy lacks head-to-head comparative trial data and is largely guided by trigger context (infection-associated favoring the less myelosuppressive anakinra approach) and institutional/specialist preference. Distinguishing MAS flare from superimposed infection remains a genuine, unresolved clinical challenge without a definitive discriminating test.

17. References

1. Autoimmune Emergencies (SLE/MAS section). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 69).
2. Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
3. Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613-2620.
4. Ravelli A, Minoia F, Davi S, et al. 2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2016;75(3):481-489.

See also: DIC (Hematology System) for the coagulopathy/hypofibrinogenemia management overlap; Acute Liver Failure (GI & Hepatology System) for hepatic involvement management; Pulmonary-Renal Syndrome and CAPS (Autoimmune & Rheumatology System) for the shared treat-on-suspicion philosophy in rheumatologic emergencies.